
Celldom, Inc Stock
Find and study cells that make diseases incurable
Sign up today and learn more about Celldom, Inc Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Celldom, Inc Stock
Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company’s TrapTx Analyzer System uniquely integrates both phenotypic and genomic data at massive scale (up to tens of thousands of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology.
Funding History
January 2017 | $225K |
---|---|
December 2017 | $225K |
September 2018 | $1.5M |
Management
Commercial Advisor
J. Kurt Jacobus
Scientific & Commercial Advisor
Myla Lai-Goldman
Technical Advisor - Systems Engineering
Emil Radulescu
Financial Advisor
Jeff Blake
Co-Founder, Chief Executive Officer
Benjamin Yellen
Co-Founder, President, & CEO
Zachary Forbes
Co-Founder
Kris Wood
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase